These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36587560)

  • 1. In vivo editing of the pan-endothelium by immunity evading simian adenoviral vector.
    Lorincz R; Alvarez AB; Walkey CJ; Mendonça SA; Lu ZH; Martinez AE; Ljungberg C; Heaney JD; Lagor WR; Curiel DT
    Biomed Pharmacother; 2023 Feb; 158():114189. PubMed ID: 36587560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient Genome Editing Achieved via Plug-and-Play Adenovirus Piggyback Transport of Cas9/gRNA Complex on Viral Capsid Surface.
    Lu ZH; Li J; Dmitriev IP; Kashentseva EA; Curiel DT
    ACS Nano; 2022 Jul; 16(7):10443-10455. PubMed ID: 35749339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical non-viral vectors exploited for
    Rouatbi N; McGlynn T; Al-Jamal KT
    Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9.
    Stephens CJ; Lauron EJ; Kashentseva E; Lu ZH; Yokoyama WM; Curiel DT
    J Control Release; 2019 Mar; 298():128-141. PubMed ID: 30771412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
    Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
    Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Gorilla Adenoviral Vector with Natural Lung Tropism Avoids Liver Toxicity and Is Amenable to Capsid Engineering and Vector Retargeting.
    Lu ZH; Dmitriev IP; Brough DE; Kashentseva EA; Li J; Curiel DT
    J Virol; 2020 May; 94(10):. PubMed ID: 32102889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.
    Ehrke-Schulz E; Schiwon M; Leitner T; Dávid S; Bergmann T; Liu J; Ehrhardt A
    Sci Rep; 2017 Dec; 7(1):17113. PubMed ID: 29215041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel System for Simple Rapid Adenoviral Vector Construction to Facilitate CRISPR/Cas9-Mediated Genome Editing.
    Bi Y; Gu L; Wang J; Chang Y; Jin M; Mao Y; Wang H; Ji G
    CRISPR J; 2021 Jun; 4(3):381-391. PubMed ID: 34077671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy.
    Wang Y; Jiang H; Li M; Xu Z; Xu H; Chen Y; Chen K; Zheng W; Lin W; Liu Z; Lin Z; Zhang M
    Gene; 2024 Nov; 927():148733. PubMed ID: 38945310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR Systems Suitable for Single AAV Vector Delivery.
    Stevanovic M; Piotter E; McClements ME; MacLaren RE
    Curr Gene Ther; 2022; 22(1):1-14. PubMed ID: 34620062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro CRISPR-Cas9-mediated efficient Ad5 vector modification.
    Tang L; Gong M; Zhang P
    Biochem Biophys Res Commun; 2016 May; 474(2):395-399. PubMed ID: 27125457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses.
    Wang D; Mou H; Li S; Li Y; Hough S; Tran K; Li J; Yin H; Anderson DG; Sontheimer EJ; Weng Z; Gao G; Xue W
    Hum Gene Ther; 2015 Jul; 26(7):432-42. PubMed ID: 26086867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.
    Park A; Lee JY
    J Microbiol; 2024 Jul; 62(7):491-509. PubMed ID: 39037484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
    Shalaby K; Aouida M; El-Agnaf O
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.